Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial
Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006139/en/
Zephyr Endobronchial Valves (Photo: Business Wire)
“The LIBERATE Study definitively proves that Zephyr Valves offer clinically meaningful improvements in three important areas for patients – the ability to breathe better, be more active, and enjoy an improved quality of life,” said the study’s lead investigator, Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University.
He continued, “All primary and secondary endpoints were met, with Zephyr Valve treatment showing significant improvement for patients across multiple measures of breathing and quality of life. The Zephyr Valve also demonstrated an acceptable safety profile given the magnitude of benefit seen in this study.”
The LIBERATE Study results were concurrently published in the American Journal of Respiratory and Critical Care Medicine and presented at the American Thoracic Society (ATS) 2018 International Conference by Dr. Criner.
A copy of the open access article can be viewed here.
LIBERATE is the first international, multicenter, randomized controlled trial to evaluate the effectiveness and safety of the Zephyr Endobronchial Valve out to one year in patients with severe heterogeneous emphysema with little to no collateral ventilation in the target lobe of the lung. The study randomized 190 patients at 24 sites, using a 2:1 randomization to Zephyr Valve treatment or medical management alone. Eligible patients were assessed for collateral ventilation using the Chartis® Pulmonary Assessment System, and only patients with little to no collateral ventilation in the target lobe were randomized.
One year after treatment, almost three times more patients treated with Zephyr Valves achieved the target improvement in lung function (≥15% increase in FEV1) compared to patients on medical management alone. In addition, Zephyr patients were able to do more daily activities, such as walking, doing chores and getting washed, with less shortness of breath than patients on medical management alone.
The most common side effect associated with the procedure was pneumothorax (air leak in the lung), which occurred in approximately one-third of patients. No intervention was required in approximately 20 percent of the incidents; the majority of the rest were addressed with standard medical management. Other side effects that happened less frequently included COPD exacerbation, pneumonia, respiratory failure and death.
Patients treated with Zephyr Valves had a statistically significant reduction in the rate of respiratory failure and a trend towards a reduction in the rate of COPD hospitalizations when compared to patients on medical management alone in the period following treatment to one year of follow-up.
Key outcomes at 12 months included:
Primary endpoint met:
- Percentage of subjects with FEV1 improvement of ≥15% (a measure of breathing): 47.7% Zephyr Valve versus 16.8% control group (p<0.001).
Secondary endpoints met – the difference between the Zephyr Valve
group and control group favored treated patients by:
- FEV1 (a measure of breathing): 0.106L (p<0.001).
- St. George’s Respiratory Questionnaire score (SGRQ, a measure of quality of life): -7.05 points (p=0.004).
- Six-Minute Walk Distance (6MWD, a measure of exercise capacity): +39.3 meters (p=0.002).
The authors of the study commented that, “Bronchoscopic lung volume reduction with Zephyr EBV (endobronchial valves) is a breakthrough approach for reducing hyperinflation in patients with severe emphysema.” Furthermore, they noted that, “The occurrence of pneumothorax does not negatively impact clinical outcomes.”
Zephyr Valves are designed for emphysema patients who are often short of breath and doing less of the things they want to do despite regular use of COPD medications and/or oxygen. The tiny, one-way valves are placed in target airways of the lungs in a short procedure that does not involve cutting to occlude, or block off, the more diseased areas. This reduces hyperinflation and allows healthier parts of the lungs to take in more air and work more effectively. They are designed to be permanent, but can easily be removed, if necessary.
Over 12,000 patients worldwide have been treated with Zephyr Valves. This treatment option is included in emphysema treatment guidance issued by leading health organizations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK’s National Institute for Health and Care Excellence (NICE). Zephyr Endobronchial Valves are the only endoscopic emphysema treatment with patient selection tools (Chartis and StratX® Lung Analysis Platform) that can accurately identify patients most likely to benefit from treatment, demonstrating 90 percent accuracy when used in combination.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.
The Zephyr Endobronchial Valve is an investigational device in the United States. Limited by U.S. law to investigational use only.
Michelle McAdam, (310) 902-1274
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Announcement by Viking Corp on Tecnotree22.6.2018 14:09 | Tiedote
In the interests of stakeholder transparency, this announcement provides background and context to Viking's file bankruptcy proceedings upon Tecnotree: As many of you will now know, Viking Corp was recently forced to file bankruptcy proceedings upon Tecnotree, which were withdrawn on the 19 June. In the interests of stakeholder transparency, we make this Announcement to provide background and context to this action. Firstly, we would reflect on the recent history of our attempts to partner with Tecnotree and all its stakeholders. Viking launched a Tender Offer (TO), having conducted detailed discussions with the Tecnotree Board and our advisors. On the basis of those discussions, we were very confident that the TO price of 10 cents per share provided truly superior value for shareholders. So did the Tecnotree Board as evidenced by their unanimous recommendation of our Offer and of course, further evidenced by the current prevailing market price. This TO was supported in the most vigoro
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme